<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35105727</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-330X</ISSN><JournalIssue CitedMedium="Internet"><Volume>93</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J Neurol Neurosurg Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>422</StartPage><EndPage>435</EndPage><MedlinePgn>422-435</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/jnnp-2021-327503</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive neurodegenerative disease, and only modest disease-modifying strategies have been established to date. Numerous clinical trials have been conducted in the past years, but have been severely hampered by the wide-ranging heterogeneity of both the biological origins and clinical characteristics of the disease. Thus, reliable biomarkers of disease activity are urgently needed to stratify patients into homogenous groups with aligned disease trajectories to allow a more effective design of clinical trial. In this review, the most promising candidate biomarkers in the cerebrospinal fluid (CSF) of patients with ALS will be summarised. Correlations between biomarker levels and clinical outcome parameters are discussed, while highlighting potential pitfalls and intercorrelations of these clinical parameters. Several CSF molecules have shown potential as biomarkers of progression and prognosis, but large, international, multicentric and longitudinal studies are crucial for validation. A more standardised choice of clinical endpoints in these studies, as well as the application of individualised models of clinical progression, would allow the quantification of disease trajectories, thereby allowing a more accurate analysis of the clinical implications of candidate biomarkers. Additionally, a comparative analysis of several biomarkers and ideally the application of a multivariate analysis including comprehensive genotypic, phenotypic and clinical characteristics collectively contributing to biomarker levels in the CSF, could promote their verification. Thus, reliable prognostic markers and markers of disease activity may improve clinical trial design and patient management in the direction of precision medicine.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Dreger</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Jena University Hospital, Jena, Th&#xfc;ringen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Steinbach</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-3936-6010</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Jena University Hospital, Jena, Th&#xfc;ringen, Germany Robert.Steinbach@med.uni-jena.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otto</LastName><ForeName>Markus</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6647-5944</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Halle (Saale), Halle (Saale), Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0003-0267-3180</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, Oxford University, Oxford, Oxfordshire, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grosskreutz</LastName><ForeName>Julian</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-9525-1424</Identifier><AffiliationInfo><Affiliation>Precision Neurology, Department of Neurology, University of Luebeck Human Medicine, Luebeck, Schleswig-Holstein, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>TURNER/OCT18/989-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>2</Day><Hour>5</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35105727</ArticleId><ArticleId IdType="pmc">PMC8921583</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2021-327503</ArticleId><ArticleId IdType="pii">jnnp-2021-327503</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Westeneng H-J, Debray TPA, Visser AE, et al. . Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol 2018;17:423&#x2013;33. 10.1016/S1474-4422(18)30089-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Berg LH, Sorenson E, Gronseth G, et al. . Revised Airlie house consensus guidelines for design and implementation of ALS clinical trials. Neurology 2019;92:e1610&#x2013;23. 10.1212/WNL.0000000000007242</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007242</ArticleId><ArticleId IdType="pmc">PMC6448453</ArticleId><ArticleId IdType="pubmed">30850440</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeckl P, Weydt P, Thal DR, et al. . Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosis. Acta Neuropathol 2020;139:119&#x2013;34. 10.1007/s00401-019-02093-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02093-x</ArticleId><ArticleId IdType="pubmed">31701227</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu S, Wuolikainen A, Wu J, et al. . Targeted multiple reaction monitoring analysis of CSF identifies UCHL1 and GPNMB as candidate biomarkers for ALS. J Mol Neurosci 2019;69:643&#x2013;57. 10.1007/s12031-019-01411-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-019-01411-y</ArticleId><ArticleId IdType="pmc">PMC6858390</ArticleId><ArticleId IdType="pubmed">31721001</ArticleId></ArticleIdList></Reference><Reference><Citation>Mellinger AL, Griffith EH, Bereman MS. Peptide variability and signatures associated with disease progression in CSF collected longitudinally from ALS patients. Anal Bioanal Chem 2020;412:5465&#x2013;75. 10.1007/s00216-020-02765-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00216-020-02765-8</ArticleId><ArticleId IdType="pubmed">32591871</ArticleId></ArticleIdList></Reference><Reference><Citation>Varghese AM, Sharma A, Mishra P, et al. . Chitotriosidase - a putative biomarker for sporadic amyotrophic lateral sclerosis. Clin Proteomics 2013;10:19. 10.1186/1559-0275-10-19</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1559-0275-10-19</ArticleId><ArticleId IdType="pmc">PMC4220794</ArticleId><ArticleId IdType="pubmed">24295388</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Feneberg E, Weishaupt J, et al. . Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry 2016;87:12&#x2013;20. 10.1136/jnnp-2015-311387</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-311387</ArticleId><ArticleId IdType="pubmed">26296871</ArticleId></ArticleIdList></Reference><Reference><Citation>Dreger M, Steinbach R, Gaur N, et al. . Cerebrospinal fluid neurofilament light chain (NFL) predicts disease aggressiveness in amyotrophic lateral sclerosis: an application of the D50 disease progression model. Front Neurosci 2021;15:651651. 10.3389/fnins.2021.651651</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2021.651651</ArticleId><ArticleId IdType="pmc">PMC8056017</ArticleId><ArticleId IdType="pubmed">33889072</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, De Schaepdryver M, Stubendorff B, et al. . Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology 2017;88:2302&#x2013;9. 10.1212/WNL.0000000000004029</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004029</ArticleId><ArticleId IdType="pubmed">28500227</ArticleId></ArticleIdList></Reference><Reference><Citation>De Schaepdryver M, Jeromin A, Gille B, et al. . Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2018;89:367&#x2013;73. 10.1136/jnnp-2017-316605</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316605</ArticleId><ArticleId IdType="pubmed">29054919</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Rumeileh S, Vacchiano V, Zenesini C, et al. . Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis. J Neurol 2020;267:1699&#x2013;708. 10.1007/s00415-020-09761-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-09761-z</ArticleId><ArticleId IdType="pubmed">32100123</ArticleId></ArticleIdList></Reference><Reference><Citation>Menke RAL, Gray E, Lu C-H, et al. . Csf neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann Clin Transl Neurol 2015;2:748&#x2013;55. 10.1002/acn3.212</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.212</ArticleId><ArticleId IdType="pmc">PMC4531057</ArticleId><ArticleId IdType="pubmed">26273687</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber S, Spotorno N, Schreiber F, et al. . Significance of CSF NFL and tau in ALS. J Neurol 2018;265:2633&#x2013;45. 10.1007/s00415-018-9043-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-9043-0</ArticleId><ArticleId IdType="pubmed">30187162</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Z-Y, Lv G-P, Gao L-N, et al. . Neurofilament subunit L levels in the cerebrospinal fluid and serum of patients with amyotrophic lateral sclerosis. Neurodegener Dis 2018;18:165&#x2013;72. 10.1159/000488681</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000488681</ArticleId><ArticleId IdType="pubmed">29898446</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaetani L, Blennow K, Calabresi P, et al. . Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 2019;90:870&#x2013;81. 10.1136/jnnp-2018-320106</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-320106</ArticleId><ArticleId IdType="pubmed">30967444</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarafino A, D'Errico E, Introna A, et al. . Diagnostic and prognostic power of CSF tau in amyotrophic lateral sclerosis. J Neurol 2018;265:2353&#x2013;62. 10.1007/s00415-018-9008-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-9008-3</ArticleId><ArticleId IdType="pubmed">30116940</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortelli R, Ruggieri M, Cortese R, et al. . Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression. Eur J Neurol 2012;19:1561&#x2013;7. 10.1111/j.1468-1331.2012.03777.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2012.03777.x</ArticleId><ArticleId IdType="pubmed">22680408</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AG, Gray E, Bampton A. Csf chitinase proteins in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2019. 10.1136/jnnp-2019-320442</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-320442</ArticleId><ArticleId IdType="pubmed">31123140</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Petzold A, S&#xfc;ssmuth SD, et al. . Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 2006;66:852&#x2013;6. 10.1212/01.wnl.0000203120.85850.54</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000203120.85850.54</ArticleId><ArticleId IdType="pubmed">16567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Andr&#xe9;s-Benito P, Dom&#xed;nguez R, Colomina MJ, et al. . Ykl40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression. Aging 2018;10:2367&#x2013;82. 10.18632/aging.101551</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.101551</ArticleId><ArticleId IdType="pmc">PMC6188478</ArticleId><ArticleId IdType="pubmed">30215603</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Verde F, Fang L, et al. . Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. J Neurol Neurosurg Psychiatry 2018;89:239&#x2013;47. 10.1136/jnnp-2017-317138</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317138</ArticleId><ArticleId IdType="pubmed">29142138</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortelli R, Copetti M, Ruggieri M, et al. . Cerebrospinal fluid neurofilament light chain levels: marker of progression to generalized amyotrophic lateral sclerosis. Eur J Neurol 2015;22:215&#x2013;8. 10.1111/ene.12421</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12421</ArticleId><ArticleId IdType="pubmed">24750431</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Ren Y, Zhu W, et al. . Phosphorylated neurofilament heavy chain levels in paired plasma and CSF of amyotrophic lateral sclerosis. J Neurol Sci 2016;367:269&#x2013;74. 10.1016/j.jns.2016.05.062</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2016.05.062</ArticleId><ArticleId IdType="pubmed">27423602</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiani A, Martinelli I, Bello L, et al. . Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: neurofilament light chain levels in definite subtypes of disease. JAMA Neurol 2017;74:525&#x2013;32. 10.1001/jamaneurol.2016.5398</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.5398</ArticleId><ArticleId IdType="pmc">PMC5822207</ArticleId><ArticleId IdType="pubmed">28264096</ArticleId></ArticleIdList></Reference><Reference><Citation>Ill&#xe1;n-Gala I, Alcolea D, Montal V, et al. . Csf sAPP&#x3b2;, YKL-40, and NFL along the ALS-FTD spectrum. Neurology 2018;91:e1619&#x2013;28. 10.1212/WNL.0000000000006383</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006383</ArticleId><ArticleId IdType="pubmed">30291183</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C-H, Macdonald-Wallis C, Gray E, et al. . Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 2015;84:2247&#x2013;57. 10.1212/WNL.0000000000001642</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001642</ArticleId><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Daughrity LM, et al. , C9ORF72 Neurofilament Study Group . Phosphorylated neurofilament heavy chain: a biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis. Ann Neurol 2017;82:139&#x2013;46. 10.1002/ana.24980</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24980</ArticleId><ArticleId IdType="pmc">PMC5676468</ArticleId><ArticleId IdType="pubmed">28628244</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Cheng B, Salachas F, et al. . Progression in ALS is not linear but is curvilinear. J Neurol 2010;257:1713&#x2013;7. 10.1007/s00415-010-5609-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-010-5609-1</ArticleId><ArticleId IdType="pubmed">20532545</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Feneberg E, Halbgebauer S, et al. . Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study. Amyotroph Lateral Scler Frontotemporal Degener 2021;22:276&#x2013;86. 10.1080/21678421.2020.1861023</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1861023</ArticleId><ArticleId IdType="pubmed">33576252</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang F, Zhu Y, Hsiao-Nakamoto J, et al. . Longitudinal biomarkers in amyotrophic lateral sclerosis. Ann Clin Transl Neurol 2020;7:1103&#x2013;16. 10.1002/acn3.51078</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51078</ArticleId><ArticleId IdType="pmc">PMC7359115</ArticleId><ArticleId IdType="pubmed">32515902</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H, Jacobsson J, Rosengren L, et al. . Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. Eur J Neurol 2007;14:1329&#x2013;33. 10.1111/j.1468-1331.2007.01972.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2007.01972.x</ArticleId><ArticleId IdType="pubmed">17903209</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AG, Gray E, Th&#xe9;z&#xe9;nas M-L, et al. . Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis. Ann Neurol 2018;83:258&#x2013;68. 10.1002/ana.25143</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25143</ArticleId><ArticleId IdType="pubmed">29331073</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, et al. . Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol 2018;84:130&#x2013;9. 10.1002/ana.25276</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25276</ArticleId><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Weydt P, Oeckl P, Huss A, et al. . Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol 2016;79:152&#x2013;8. 10.1002/ana.24552</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24552</ArticleId><ArticleId IdType="pubmed">26528863</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeckl P, Weydt P, Steinacker P, et al. . Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. J Neurol Neurosurg Psychiatry 2019;90:4&#x2013;10. 10.1136/jnnp-2018-318868</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318868</ArticleId><ArticleId IdType="pubmed">30224549</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Lombardi V, et al. . Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph Lateral Scler Frontotemporal Degener 2019;20:538&#x2013;48. 10.1080/21678421.2019.1646769</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1646769</ArticleId><ArticleId IdType="pmc">PMC6768722</ArticleId><ArticleId IdType="pubmed">31432691</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D-W, Ren H, Jeromin A, et al. . Diagnostic performance of neurofilaments in Chinese patients with amyotrophic lateral sclerosis: a prospective study. Front Neurol 2018;9:726. 10.3389/fneur.2018.00726</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.00726</ArticleId><ArticleId IdType="pmc">PMC6121092</ArticleId><ArticleId IdType="pubmed">30210445</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, et al. . Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med 2020;383:109&#x2013;19. 10.1056/NEJMoa2003715</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman M, Elman L, McCluskey L, et al. . Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis. JAMA Neurol 2014;71:442&#x2013;8. 10.1001/jamaneurol.2013.6064</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.6064</ArticleId><ArticleId IdType="pmc">PMC3989393</ArticleId><ArticleId IdType="pubmed">24492862</ArticleId></ArticleIdList></Reference><Reference><Citation>Paladino P, Valentino F, Piccoli T, et al. . Cerebrospinal fluid tau protein is not a biological marker in amyotrophic lateral sclerosis. Eur J Neurol 2009;16:257&#x2013;61. 10.1111/j.1468-1331.2008.02405.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2008.02405.x</ArticleId><ArticleId IdType="pubmed">19138331</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanznaster D, Hergesheimer RC, Bakkouche SE, et al. . A&#x3b2;1-42 and tau as potential biomarkers for diagnosis and prognosis of amyotrophic lateral sclerosis. Int J Mol Sci 2020;21. 10.3390/ijms21082911. [Epub ahead of print: 21 Apr 2020].</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21082911</ArticleId><ArticleId IdType="pmc">PMC7216266</ArticleId><ArticleId IdType="pubmed">32326346</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine TD, Bowser R, Hank N, et al. . A pilot trial of memantine and riluzole in ALS: correlation to CSF biomarkers. Amyotroph Lateral Scler 2010;11:514&#x2013;9. 10.3109/17482968.2010.513052</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.513052</ArticleId><ArticleId IdType="pubmed">20839903</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu L, An J, Kovalik T, et al. . Cross-Sectional and longitudinal measures of chitinase proteins in amyotrophic lateral sclerosis and expression of CHI3L1 in activated astrocytes. J Neurol Neurosurg Psychiatry 2020;91:350&#x2013;8. 10.1136/jnnp-2019-321916</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-321916</ArticleId><ArticleId IdType="pmc">PMC7147184</ArticleId><ArticleId IdType="pubmed">31937582</ArticleId></ArticleIdList></Reference><Reference><Citation>Varghese AM, Ghosh M, Bhagat SK, et al. . Chitotriosidase, a biomarker of amyotrophic lateral sclerosis, accentuates neurodegeneration in spinal motor neurons through neuroinflammation. J Neuroinflammation 2020;17:232. 10.1186/s12974-020-01909-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-020-01909-y</ArticleId><ArticleId IdType="pmc">PMC7412641</ArticleId><ArticleId IdType="pubmed">32762702</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray E, Thompson AG, Wuu J, et al. . Csf chitinases before and after symptom onset in amyotrophic lateral sclerosis. Ann Clin Transl Neurol 2020;7:1296&#x2013;306. 10.1002/acn3.51114</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51114</ArticleId><ArticleId IdType="pmc">PMC7448184</ArticleId><ArticleId IdType="pubmed">32666680</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B, De Schaepdryver M, Dedeene L, et al. . Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry 2019;90:1338-1346. 10.1136/jnnp-2018-319586</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319586</ArticleId><ArticleId IdType="pubmed">31175169</ArticleId></ArticleIdList></Reference><Reference><Citation>Bereman MS, Beri J, Enders JR, et al. . Machine learning reveals protein signatures in CSF and plasma fluids of clinical value for ALS. Sci Rep 2018;8:16334. 10.1038/s41598-018-34642-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-34642-x</ArticleId><ArticleId IdType="pmc">PMC6218542</ArticleId><ArticleId IdType="pubmed">30397248</ArticleId></ArticleIdList></Reference><Reference><Citation>Tateishi T, Yamasaki R, Tanaka M, et al. . Csf chemokine alterations related to the clinical course of amyotrophic lateral sclerosis. J Neuroimmunol 2010;222:76&#x2013;81. 10.1016/j.jneuroim.2010.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2010.03.004</ArticleId><ArticleId IdType="pubmed">20381883</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka M, Kikuchi H, Ishizu T, et al. . Intrathecal upregulation of granulocyte colony stimulating factor and its neuroprotective actions on motor neurons in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2006;65:816&#x2013;25. 10.1097/01.jnen.0000232025.84238.e1</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.jnen.0000232025.84238.e1</ArticleId><ArticleId IdType="pubmed">16896315</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata T, Nagano I, Shiote M, et al. . Elevation of MCP-1 and MCP-1/VEGF ratio in cerebrospinal fluid of amyotrophic lateral sclerosis patients. Neurol Res 2007;29:772&#x2013;6. 10.1179/016164107X229795</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/016164107X229795</ArticleId><ArticleId IdType="pubmed">17672928</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J, Yang X, Gao L, et al. . Evaluating the levels of CSF and serum factors in ALS. Brain Behav 2017;7:e00637. 10.1002/brb3.637</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.637</ArticleId><ArticleId IdType="pmc">PMC5346523</ArticleId><ArticleId IdType="pubmed">28293476</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell RM, Freeman WM, Randazzo WT, et al. . A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology 2009;72:14&#x2013;19. 10.1212/01.wnl.0000333251.36681.a5</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000333251.36681.a5</ArticleId><ArticleId IdType="pubmed">18987350</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehnert S, Costa J, de Carvalho M, et al. . Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:344&#x2013;50. 10.3109/21678421.2014.884592</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.884592</ArticleId><ArticleId IdType="pubmed">24575871</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Gao L, Wu X, et al. . Increased levels of MIP-1&#x3b1; in CSF and serum of ALS. Acta Neurol Scand 2016;134:94&#x2013;100. 10.1111/ane.12513</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.12513</ArticleId><ArticleId IdType="pubmed">26427609</ArticleId></ArticleIdList></Reference><Reference><Citation>Su XW, Simmons Z, Mitchell RM, et al. . Biomarker-Based predictive models for prognosis in amyotrophic lateral sclerosis. JAMA Neurol 2013;70:1505&#x2013;11. 10.1001/jamaneurol.2013.4646</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.4646</ArticleId><ArticleId IdType="pubmed">24145899</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Zhao W, Neal DW, et al. . Elevated acute phase proteins reflect peripheral inflammation and disease severity in patients with amyotrophic lateral sclerosis. Sci Rep 2020;10:15295. 10.1038/s41598-020-72247-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-72247-5</ArticleId><ArticleId IdType="pmc">PMC7499429</ArticleId><ArticleId IdType="pubmed">32943739</ArticleId></ArticleIdList></Reference><Reference><Citation>Olesen MN, Wuolikainen A, Nilsson AC, et al. . Inflammatory profiles relate to survival in subtypes of amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm 2020;7. 10.1212/NXI.0000000000000697. [Epub ahead of print: 02 03 2020].</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000697</ArticleId><ArticleId IdType="pmc">PMC7136052</ArticleId><ArticleId IdType="pubmed">32123048</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Mora G, La Bella V, et al. . Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: clinical and biological results from a prospective multicenter study. Muscle Nerve 2011;43:189&#x2013;95. 10.1002/mus.21851</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21851</ArticleId><ArticleId IdType="pubmed">21254083</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa T, Matsui N, Fujita K, et al. . Csf cytokine profile distinguishes multifocal motor neuropathy from progressive muscular atrophy. Neurol Neuroimmunol Neuroinflamm 2015;2:e138. 10.1212/NXI.0000000000000138</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000138</ArticleId><ArticleId IdType="pmc">PMC4529282</ArticleId><ArticleId IdType="pubmed">26280014</ArticleId></ArticleIdList></Reference><Reference><Citation>Wosiski-Kuhn M, Robinson M, Strupe J, et al. . IL6 receptor358Ala variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm 2019;6:e631. 10.1212/NXI.0000000000000631</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000631</ArticleId><ArticleId IdType="pmc">PMC6865852</ArticleId><ArticleId IdType="pubmed">31611269</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusina R, Ridzon P, Kulist'&#xe1;k P, et al. . Relationship between ALS and the degree of cognitive impairment, markers of neurodegeneration and predictors for poor outcome. A prospective study. Eur J Neurol 2010;17:23&#x2013;30. 10.1111/j.1468-1331.2009.02717.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2009.02717.x</ArticleId><ArticleId IdType="pubmed">19572947</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Fang L, Kuhle J, et al. . Soluble beta-amyloid precursor protein is related to disease progression in amyotrophic lateral sclerosis. PLoS One 2011;6:e23600. 10.1371/journal.pone.0023600</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0023600</ArticleId><ArticleId IdType="pmc">PMC3156148</ArticleId><ArticleId IdType="pubmed">21858182</ArticleId></ArticleIdList></Reference><Reference><Citation>I&#x142;zecka J. Cerebrospinal fluid vascular endothelial growth factor in patients with amyotrophic lateral sclerosis. Clin Neurol Neurosurg 2004;106:289&#x2013;93. 10.1016/j.clineuro.2003.12.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2003.12.007</ArticleId><ArticleId IdType="pubmed">15297002</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau C, Devos D, Brunaud-Danel V, et al. . Paradoxical response of VEGF expression to hypoxia in CSF of patients with ALS. J Neurol Neurosurg Psychiatry 2006;77:255&#x2013;7. 10.1136/jnnp.2005.070904</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2005.070904</ArticleId><ArticleId IdType="pmc">PMC2077591</ArticleId><ArticleId IdType="pubmed">16421133</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Z, Gao L, Guo J, et al. . bFGF in the CSF and serum of sALS patients. Acta Neurol Scand 2015;132:171&#x2013;8. 10.1111/ane.12381</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.12381</ArticleId><ArticleId IdType="pubmed">25631037</ArticleId></ArticleIdList></Reference><Reference><Citation>Ru&#xe9; L, Oeckl P, Timmers M, et al. . Reduction of ephrin-A5 aggravates disease progression in amyotrophic lateral sclerosis. Acta Neuropathol Commun 2019;7:114. 10.1186/s40478-019-0759-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0759-6</ArticleId><ArticleId IdType="pmc">PMC6626434</ArticleId><ArticleId IdType="pubmed">31300041</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu B, De SK, Kulinich A, et al. . Potent and selective EphA4 agonists for the treatment of ALS. Cell Chem Biol 2017;24:293&#x2013;305. 10.1016/j.chembiol.2017.01.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2017.01.006</ArticleId><ArticleId IdType="pmc">PMC6522132</ArticleId><ArticleId IdType="pubmed">28196613</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, Cudkowicz ME, Windebank AJ, et al. . NurOwn, phase 2, randomized, clinical trial in patients with ALS: safety, clinical, and biomarker results. Neurology 2019;93:e2294&#x2013;305. 10.1212/WNL.0000000000008620</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008620</ArticleId><ArticleId IdType="pmc">PMC6937497</ArticleId><ArticleId IdType="pubmed">31740545</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumder V, Gregory JM, Barria MA, et al. . Tdp-43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis. BMC Neurol 2018;18:90. 10.1186/s12883-018-1091-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-018-1091-7</ArticleId><ArticleId IdType="pmc">PMC6027783</ArticleId><ArticleId IdType="pubmed">29954341</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Gray E, Ansorge O, et al. . Towards a TDP-43-Based biomarker for ALS and FTLD. Mol Neurobiol 2018;55:7789&#x2013;801. 10.1007/s12035-018-0947-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-0947-6</ArticleId><ArticleId IdType="pmc">PMC6132775</ArticleId><ArticleId IdType="pubmed">29460270</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeter LHH, Gendron TF, Sias AC, et al. . Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers. Ann Clin Transl Neurol 2018;5:583&#x2013;97. 10.1002/acn3.559</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.559</ArticleId><ArticleId IdType="pmc">PMC5945959</ArticleId><ArticleId IdType="pubmed">29761121</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Chew J, Stankowski JN, et al. . Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Sci Transl Med 2017;9. 10.1126/scitranslmed.aai7866. [Epub ahead of print: 29 03 2017].</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aai7866</ArticleId><ArticleId IdType="pmc">PMC5576451</ArticleId><ArticleId IdType="pubmed">28356511</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomo V, Tosat-Bitrian C, Nozal V, et al. . Tdp-43: a key therapeutic target beyond amyotrophic lateral sclerosis. ACS Chem Neurosci 2019;10:1183&#x2013;96. 10.1021/acschemneuro.9b00026</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.9b00026</ArticleId><ArticleId IdType="pubmed">30785719</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (phase II study). Amyotroph Lateral Scler 2006;7:241&#x2013;5. 10.1080/17482960600881870</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960600881870</ArticleId><ArticleId IdType="pubmed">17127563</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohta Y, Yamashita T, Nomura E, et al. . Improvement of a decreased anti-oxidative activity by edaravone in amyotrophic lateral sclerosis patients. J Neurol Sci 2020;415:116906. 10.1016/j.jns.2020.116906</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2020.116906</ArticleId><ArticleId IdType="pubmed">32446009</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group, Edaravone (MCI-186) ALS 19 Study Group . Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017;16:505&#x2013;12. 10.1016/S1474-4422(17)30115-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Opa&#x10d;i&#x107; M, Stevi&#x107; Z, Ba&#x161;&#x10d;arevi&#x107; V, et al. . Can oxidation-reduction potential of cerebrospinal fluid be a monitoring biomarker in amyotrophic lateral sclerosis? Antioxid Redox Signal 2018;28:1570&#x2013;5. 10.1089/ars.2017.7433</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2017.7433</ArticleId><ArticleId IdType="pubmed">29113448</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikenaka K, Atsuta N, Maeda Y, et al. . Increase of arginine dimethylation correlates with the progression and prognosis of ALS. Neurology 2019;92:e1868&#x2013;77. 10.1212/WNL.0000000000007311</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007311</ArticleId><ArticleId IdType="pubmed">30867270</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, Al Khleifat A, Meurgey J-H, et al. . Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol 2018;17:416&#x2013;22. 10.1016/S1474-4422(18)30054-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30054-1</ArticleId><ArticleId IdType="pmc">PMC5899963</ArticleId><ArticleId IdType="pubmed">29525492</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>